剖宫产产后出血预防药物的网状Meta分析
该网状Meta分析纳入46项随机对照试验共7368名剖宫产产妇,比较缩宫素、卡贝缩宫素、米索前列醇等药物预防产后出血的效果。卡贝缩宫素在减少估计失血量和额外宫缩剂需求方面可能优于缩宫素,但失血量减少幅度临床意义有限;缩宫素作为负荷剂量给药时效果更佳。
要点
- 卡贝缩宫素可能减少估计失血量54.83 mL(95%CI 26.48-143.78),但临床意义有限。
- 卡贝缩宫素每1000例可减少185次额外宫缩剂需求(95%CI 130-218)。
- 缩宫素负荷剂量给药在两项主要结局中成为最佳宫缩剂概率更高。
核心结论
- 卡贝缩宫素可能是减少失血量和额外宫缩剂需求最有效的药物。
- 缩宫素以负荷剂量给药时可能更有效。
研究设计与样本
- 系统综述与网状Meta分析,检索Cochrane Central、Embase和MEDLINE至2020年5月。
- 纳入46项随机对照试验共7368名剖宫产产妇,比较缩宫素、卡贝缩宫素、米索前列醇、麦角新碱、卡前列素或联合用药。
- 失血量网络纳入21项试验(6种药物,3665名参与者),额外宫缩剂网络纳入37项试验(8种药物,6193名参与者)。
主要发现
- 卡贝缩宫素相比缩宫素减少估计失血量54.83 mL(95%CI 26.48-143.78),但临床意义有限。
- 卡贝缩宫素每1000例减少额外宫缩剂需求185次(95%CI 130-218)。
- 米索前列醇、麦角新碱及缩宫素联合麦角新碱可能劣于缩宫素,缩宫素联合米索前列醇确定劣于缩宫素。
- 卡前列素、麦角新碱和安慰剂在额外宫缩剂需求方面确定劣于缩宫素。
关键数值与推荐
- 主要结局为估计失血量和额外宫缩剂需求,次要结局包括恶心和产后出血>1000 mL。
- 采用CINeMA和GRADE方法评估证据质量。
临床怎么用
- 剖宫产预防产后出血可考虑卡贝缩宫素,但需权衡失血量减少的有限临床意义。
- 缩宫素作为负荷剂量起始可能提高预防效果。
局限性
- 证据确定性受限于网状Meta分析方法学局限。
- 手术情境和缩宫素给药策略的影响通过敏感性分析探索,但可能残留混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum hemorrhage causes a quarter of global maternal deaths. The World Health Organization recommends oxytocin as the first line agent to prevent hemorrhage during cesarean delivery. However, some randomized controlled trials suggest that other uterotonics are superior. OBJECTIVE: We conducted a network meta-analysis comparing the ability of pharmacologic agents to reduce blood loss and minimize the need for additional uterotonics during cesarean delivery. DATA SOURCES: We searched the Cochrane Central Register of Controlled Trials, Embase, and MEDLINE databases from inception to May 2020. STUDY ELIGIBILITY CRITERIA: We included randomized controlled trials that compared oxytocin, carbetocin, misoprostol, ergometrine, carboprost, or combinations of these in the prevention of postpartum hemorrhage during cesarean delivery. METHODS: We performed a systematic review followed by an NMA in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Quality of the evidence was assessed with the Confidence in Network Meta-Analysis approach and Grading of Recommendations, Assessment, Development and Evaluations tool within the summary of findings table. Our primary outcomes were the estimated blood loss and need for additional uterotonics. Secondary outcomes included nausea and postpartum hemorrhage of >1000 mL. We performed sensitivity analyses to explore the influence of surgical context and oxytocin administration strategy. RESULTS: A total of 46 studies with 7368 participants were included. Of those, 21 trials (6 agents and 3665 participants) formed the "estimated blood loss" network and, considering the treatment effects, certainty in the evidence, and surface under the cumulative ranking curve scores, carbetocin was assessed to probably be superior to oxytocin, but only in reducing the estimated blood loss by a clinically insignificant volume (54.83 mL; 95% confidence interval, 26.48-143.78). Misoprostol, ergometrine, and the combination of oxytocin and ergometrine were assessed to probably be inferior, whereas the combination of oxytocin and misoprostol was assessed to definitely be inferior to oxytocin. A total of 37 trials (8 agents and 6193 participants) formed the "additional uterotonic" network and, again, carbetocin was assessed to probably be superior to oxytocin, requiring additional uterotonics 185 (95% confidence interval, 130-218) fewer times per 1000 cases. Oxytocin plus misoprostol, oxytocin plus ergometrine, and misoprostol were assessed to probably be inferior, whereas carboprost, ergometrine, and the placebo were definitely inferior to oxytocin. For both primary outcomes, oxytocin administration strategies had a higher probability of being the best uterotonic, if initiated as a bolus. CONCLUSION: Carbetocin is probably the most effective agent in reducing blood loss and the need for additional uterotonics. Oxytocin appears to be more effective when initiated as a bolus.
引用
- Jaffer D, Singh PM, Aslam A, et al. Preventing postpartum hemorrhage after cesarean delivery: a network meta-analysis of available pharmacologic agents. Am J Obstet Gynecol. 2021. PMID: 34534498. doi:10.1016/j.ajog.2021.08.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。